In the context of COVID-19 severity and mortality, both mACE2 and sACE2 counteract the effects of its homolog angiotensin-converting enzyme (ACE) within renin-angiotensin-aldosterone system (RAAS) axis, decreasing the level of angiotensin (Ang) II in favor of Ang (1–7). The gene discussed is ACE; the disease is COVID-19.